

# **Clinical Criteria for the Determination of Death**

WHO Technical Expert Consultation

WHO headquarters, Geneva, Switzerland

22-23 September 2014



WHO/HIS/SDS/2017.5

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules>).

**Suggested citation.** Clinical criteria for the determination of death. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland.

**Introduction**

Death is an everyday medical occurrence that has social, legal, religious and cultural consequences requiring common clinical standards for its diagnosis and legal regulation, since death certification can vary quite widely among countries. The certification of death of an individual, namely the medical act which provides a written record of a person's death diagnosis, has been a clinical practice for centuries. This diagnosis generally leaves few or no doubts. However, despite scientific progress in the last few decades, including developments in life-support technology, there remain, at present, big variations in the diagnosis criteria applied in each country, and so in their legal regulations, which can result in misunderstandings of the public and even among health care professionals. Defining the moment of death is important to avoid the use of unnecessary medical interventions on patients who have already died. Furthermore, this is important to ensure that the process of organ donation is clear and transparent.

Death is a process involving cessation of physiological functions, and the determination of death is the final event in that process. For most people, death takes occurs with the confirmation of irreversible cessation of cardiorespiratory function.

In the second half of the twentieth century, the use of mechanical ventilation and cardiovascular support conducted in intensive care units, began to allow maintenance of the cardiac activity of patients with serious brain injuries who had cerebral circulatory arrest, no encephalic functions and an absence of spontaneous breathing. It has become scientifically evident that death was a result of the irreversible loss of the functions in the brain, either from an intra-cranial cause (devastating brain injury) or extra-cranial cause (absence of circulation).

To define the precise moment when death occurs can be difficult and should be based on the best available scientific evidence. This important medical occurrence has evolved over the last two decades in parallel with medical progress, the development of ancillary tests and the need for a certain and immediate diagnosis. There are numerous ways of dying but just one way to be dead. Therefore, the minimum determination of death criteria should be rigorous, global, and acceptable for medical practice worldwide, while remaining respectful of diversities. It is of central importance to achieve international consensus on the clinical criteria for the determination of death to maintain public trust and promote ethical practices which respect the fundamental rights of people and promote quality health services.

The aim of this technical expert consultation was to decipher this issue and reach universally accepted criteria.

## Methodology

On 22-23 September 2014, the Department of Service Delivery and Safety at the World Health Organization organized a consultation which aimed to contribute to building a global agreement on the clinical criteria that should apply in the determination of death. This meeting built on previous consultations, as well as on a Cochrane literature review completed in 2014 (<http://www.who.int/servicedeliverysafety/determination-death-review/en/>) Twenty independent experts from all six WHO Regions were invited to attend, to formulate recommendations to define the procedures that should be in place to ensure the appropriate implementation of these clinical criteria in different settings. This meeting brought expertise and experience from the different regions of the world with the aim of harmonizing different practices. Participants were encouraged to focus on the algorithms that were distributed in advance of the meeting, in order to identify and resolve any areas of disagreement while keeping an adequate focus on the main targets of the subject.

## General Discussion

Participants agreed on several general points, including the following:

- Although there are different ways to determine death, there is only one way of being dead; thus, the two classic algorithms of “brain death” and “circulatory death” initially presented should merge into a single end point identified as “death” and should not imply that “brain death” and “circulatory death” are two distinct phenomena.
- The same definition of death should apply everywhere, even if some of the tests used to confirm death may not be available in all settings.
- The process of determining death should not vary depending on whether the patient’s organs will be retrieved or not.
- The algorithms should identify the tests that need to be conducted at each stage of the process, but they should not attempt to specify the details on how each test should be performed.
- The algorithms should be free-standing documents that do not require cross-references to other guidelines.
- The algorithms should apply to both adults and children.
- A checklist could be developed to facilitate the implementation of the different components described in the algorithms.

Algorithms distributed in advance were discussed in detail, in order to build new ones (annexes 1, 1A and 1B ) based on the general consensus reached.

### **Algorithm on cardiocirculatory death (see Annex 1A)**

Participants agreed on the following:

**A.** That the algorithm should begin by identifying the essential characteristics of cardiocirculatory arrest, but it should not attempt to provide detail on the process by which cardiocirculatory arrest is confirmed. Consistent with guidelines issued by the International Liaison Committee on Resuscitation (ILCOR), cardiocirculatory arrest should be defined by the following features: *(see algorithm box 4)*

- (1) unresponsiveness
- (2) absence of breathing or only occasional gasps, and
- (3) absence of circulation.

If the patient is successfully resuscitated following cardiocirculatory arrest, the process of determining death does obviously not start. As such, in order for the practitioner to proceed with the algorithm, one of two things must occur:

- (1) cardiopulmonary resuscitation (CPR) is not attempted; or
- (2) CPR is attempted but fails.

**B.** The algorithm should identify these two circumstances but should not attempt to provide detail on all the factors that might lead practitioners to forego CPR or to determine that it has failed.

For the circumstance “CPR not attempted,” the algorithm should provide a general description of the main reasons for foregoing CPR. These could include:

- (1) the individual has a do-not-resuscitate (DNR) order or for other reasons does not meet the criteria for attempting CPR; or
- (2) treatment aimed at sustaining life has been withdrawn, allowing death to occur.

**C.** It is not necessary for the algorithm to specify the circumstances in which life-sustaining treatment can legitimately be withdrawn. Instead, it is assumed that treatment will be withdrawn only for legitimate reasons (e.g., pursuant to an advance directive or based on a medical judgment that the treatment has become unnecessary).

**D.** Similarly, for the circumstance of “CPR failed,” the algorithm should not attempt to provide details on the circumstances in which a CPR attempt should be stopped.

This issue lies outside the scope of the algorithm and is already the subject of other international guidelines, so was not investigated further.

Once either of the above two circumstances have occurred (no CPR attempted or CPR attempts failed), the next step in the process is to confirm the absence of circulation through clinical and, in some cases, instrumental tests. Participants agreed to eliminate the distinction in the draft algorithm between the tests to be used in primary care versus hospital settings. First, the distinction is misleading because the clinical tests that are used in primary care settings should also be used in the hospital context. Second, the fact that a patient is in a hospital does not necessarily mean that additional instrumental tests should be used. For example, an ECG might be used for a patient who arrests in an intensive care unit, but not for an elderly cancer patient in the general ward whose death is anticipated.

**E.** For all patients, regardless of setting, the absence of circulation should be confirmed by a clinical diagnosis that includes: (*algorithm box 5*)

- (1) absence of a central pulse on palpation and
- (2) absence of heart sound on auscultation
- (3) absence of breathing and
- (4) absence of pupillary responses to light.

The algorithm should then state that one or more of the following instrumental tests should be performed if indicated: (*algorithm box 6*)

- (1) asystole or pulseless electrical activity on a continuous ECG display; and/or
- (2) absence of pulsatile flow during intra-arterial pressure monitoring; and/or
- (3) absence of contractile activity using echocardiography.

Instrumental tests are not mandatory since diagnosis can be made without them. The instrumental tests would, however, be indicated for patients on advanced life support therapies or for whom life-sustaining treatment is withdrawn in a critical care setting. In critical care, the use of instrumental tests seems reasonable since all patients are monitored and it makes sense to use these monitors to perform the diagnosis.

Practitioners may choose to perform one, two, or three of the instrumental tests, depending on clinical judgment and situation.

Once the clinical and, if necessary, instrumental tests have been performed, it is then necessary to wait several minutes to ensure that there is no spontaneous return of cardiac or respiratory function. This period is particularly important with children. The

minimum waiting time should be five minutes, but countries can choose to require a longer waiting period. The determination of death should not be made until the waiting

period has elapsed, with the obvious exception of people whose body is discovered long after their death.

The initial draft algorithm presented a “Yes/No” option after the five-minute waiting period, and directed practitioners to wait a “further five minutes” if spontaneous cardiac or respiratory activity occurred during the initial five-minute wait. It was concluded that this section of the algorithm should be eliminated. If the patient has a spontaneous return of cardiac or respiratory activity during the five-minute waiting period, the process of determining death should stop. If the patient goes into cardiac arrest again, the determination should start again from the beginning of the algorithm.

The draft algorithm also specified certain clinical tests that would be performed after the five-minute waiting period. Participants agreed that this approach did not make sense, as a complete diagnosis of death should be made before the five-minute waiting period begins. They therefore agreed to move all of the clinical tests to earlier in the algorithm, during the process where absence of circulatory function is confirmed.

### **Algorithm on neurological arrest (Annex 1B)**

Participants agreed on the following:

1.- The “brain death” algorithm should be reformulated to make clear that its purpose is not to identify a unique “type” of death, but rather to explain how death can be determined in cases of “neurological arrest”, when the traditional cardiocirculatory criteria of death cannot be applied. Rather than providing a flow chart of specific steps to be performed in a particular sequence, the algorithm should identify the three general components of the process, which include:

- (1) the basic requirements that must exist for triggering the algorithm;
- (2) the clinical examination and diagnosis; and
- (3) confirmatory testing to ensure irreversibility.

The first component (*algorithm box 1*), namely the basic requirements, should include both the diagnosis of neurological arrest and the evaluations necessary to ensure that no confounding conditions are present. A diagnosis of neurological arrest can be made if the etiology of coma is known from a clinical assessment or neuroimaging, or if there is catastrophic structural injury to the central nervous system. In order to ensure the absence of confounding conditions, the practitioner must check for:

- hemodynamic stability

- adequate oxygenation and ventilation
- absence of severe hydroelectrolytic and acid-base equilibrium alterations
  
- absence of hypothermia (defined as temperature <32° C)
- absence of severe metabolic and endocrinological alterations
- absence of toxic substances and their effects, and
- absence of clinically significant neuromuscular blockers and neurodepressant drugs of the central nervous system.

Although not stated in the algorithm, it is implicit that there should be a waiting period before the clinical examination, to ensure that the preconditions described above have been met. The appropriate waiting period will be longer for children than for adults.

The second component of the algorithm: (*algorithm box 2*), clinical diagnosis, consists of three parts:

- examination of coma;
- confirmation of absence of brain stem reflexes;
- apnoea test.

The algorithm should simply list these three elements. For the stem reflexes tests, the general preference is to use mechanical testing of the vestibulo-ocular reflex, but if the patient's condition makes performing the test dangerous or difficult, caloric testing can be used instead. Some participants suggested that it should not be compulsory to include the oculocephalic reflex or gap reflex tests.

The apnoea test should be the last test performed. Participants noted that this test is somewhat controversial because it is theoretically possible that if a patient is not dead before the test is performed, the test itself could be harmful. In exceptional cases, if it is not possible to accomplish the apnoea test safely, practitioners may choose to wait to perform it once confirmatory testing with instrumental tests has been performed.

Participants considered the usefulness of the atropine test from the algorithm, although this test was included in the draft algorithm it is not used in many countries because it is prone to both false positives and negatives. However some countries still use the atropine test and find it valuable.

The final component of the algorithm is confirmatory testing: (*algorithm box 3*), which can include a second clinical examination and/or instrumental tests, depending on the circumstances. In cases where a primary supratentorial lesion or secondary brain damage has been confirmed, instrumental testing is usually not necessary. Instead, practitioners can either use instrumental testing, if it is available, or conduct a second clinical examination following an observation period. The length of the observation period should be based on clinical judgment, depending on the etiology of coma and the



patient's age. The second clinical examination should include all of the elements of the initial examination, including a second apnoea test.

There are, however, circumstances where using instrumental tests should be mandatory. First, in cases involving a primary infratentorial lesion, instrumental tests are needed to confirm an absence of function in the hemispheric regions. This is because the clinical examination focuses solely on the brain stem. In the absence of direct evidence of injury to the hemisphere, the clinical examination alone is insufficient to confirm that the standard of whole brain death (as opposed to merely brain stem death) has been met.

Second, instrumental tests may even be necessary in cases which do not involve primary infratentorial lesions. For example, in some situations, such as a patient whose eyes have been damaged, it may be impossible to perform the necessary clinical examinations. In other situations, it may not be possible to exclude all confounding conditions, such as when it is unclear whether there are drugs present that could suppress central nervous system function.

If it is impossible to determine whether the patient has suffered a primary infratentorial lesion or hemispheric damage, practitioners should err on the side of caution and proceed as if the patient has suffered an infratentorial lesion. Thus, in these situations, instrumental tests should be performed.


In the event that instrumental tests are used, only one test should be considered necessary. There is no single instrumental test appropriate to all situations; the choice of test should depend on the context, pathology, and resources available. The reliability of tests can be operator-dependent, so it is important to ensure that the test is administered by someone with the skills necessary to obtain reliable results.

In exceptional situations, instrumental tests may be necessary but unavailable. In these cases, death cannot be determined based on neurological criteria, because there would be a small likelihood that the determination would be incorrect. Instead, determination of death should be postponed until the patient suffers cardiocirculatory arrest, at which point the determination would follow the cardiocirculatory arrest algorithm.

ANNEX 1


**Clinical determination of death: two different workflows but a common end point - death**

**Process for the clinical determination of death**




ANNEX 1A

**Process for the clinical determination of death**



ANNEX 1B

Process for the clinical determination of death



**List of participants****Dr Akm Akhtarzzuman**

Bangabandhu Sheikh Mujib Medical  
University  
Shahbag, Dhaka-1000  
Bangladesh

Email: akhtaruzzaman.akm@gmail.com

**Dr María Elisa Barone**

Head, Department of Standards and  
Training National Institute for Excision and  
Implants  
Argentina

Email: mebarone@incuca.gov.ar

**Dr Sadek Beloucif**

Head of Intensive Care and Anaesthesia  
Units  
Bobigny Hospital  
France

Email: sadek.beloucif@avc.aphp.fr

**Dr David Carballo**

Cardiology Division  
Geneva University Hospitals (HUG)  
Rue Gabrielle Perret-Gentil 4  
1205 Geneva  
Switzerland

Email: David.carballo@hcuge.ch

**Prof Carl H. Coleman (Rapporteur)**

Professor of Law  
Academic Director, Division of Online  
Learning  
Seton Hall Law School  
One Newark Center  
Newark, NJ 07102  
United States of America

Email: carlhcoleman@gmail.com

**Dr Gabriel R. De Freitas**

Institute of Research and Education  
Rua Baronesa de Pocone 222,201-1  
Rio de Janeiro  
Postal code 22471270  
Brazil

Email : grdefreitas@gmail.com

**Prof Geoffrey Dobb**

Head, Critical Care and Intensive Care  
Royal Perth Hospital  
Wellington Street Campus  
GPO Box X2213  
Perth, Western Australia 6001  
Australia

Email: [Geoffrey.Dobb@health.wa.gov.au](mailto:Geoffrey.Dobb@health.wa.gov.au)

**Dr Nabil El Askalany**

President of Egyptian Society  
of Anesthesiologists  
28, Obour Gardens Bldgs, P.O.B 167  
Panorma Oct,  
Nasr City, Cairo  
Egypt

Email: [askalanyn@gmail.com](mailto:askalanyn@gmail.com)

**Dr Lee Ilhak**

Department of Medical Ethics and Law  
College of Medicine Yonsei University  
408 Administration B/D Health Sytem 50  
Yonsei-ro Seodaemun-gu  
Republic of Korea

Email: [ilhak.lee@gmail.com](mailto:ilhak.lee@gmail.com)

**Dr Ari Joffe**

Pediatric Critical Care  
University of Alberta and Stollery  
Children's Hospital  
8440 112 Street  
Edmonton, Alberta  
Canada

Email: [Ari.Joffe@albertahealthservices.ca](mailto:Ari.Joffe@albertahealthservices.ca)

**Prof Aina Christina Lundren Steel**

University of the Witwatersrand  
P.O. Box 14504  
Zuurfontein 1912  
South Africa

Email: [Chris.Lundgren@wits.ac.za](mailto:Chris.Lundgren@wits.ac.za)

**Dr Ben-Yan Luo**

Chief Neurology  
Zhejiang University  
38 Zheda Rd, Xihu  
Hangzhou, Zhejiang 310027  
China

Email: [luobenyan@zju.edu.cn](mailto:luobenyan@zju.edu.cn)

**Prof Walid Naija**

Department of Anesthesiology  
Sahloul Hospital  
Sousse  
Tunisia

Email: [walidnaija@yahoo.fr](mailto:walidnaija@yahoo.fr)

**Dr Margaret Okello**

Department of Anaesthesia  
Mulago National Referral Hospital  
P.O.Box 7051, Kampala  
Ouganda

Email: [magokello@yahoo.com](mailto:magokello@yahoo.com)

**Dr Nicola Petrucci**

Head, Anaesthesia and Intensive Care  
Azienda Ospedaliera Desenzano  
Loc. Montecroce,1. 25015 Desenzano  
Italy

Email: [ni.petrucci@tiscali.it](mailto:ni.petrucci@tiscali.it)

**Dr Ricard Valero**

Intensive care  
Hospital Clínic de Barcelona  
Villarroel 170,  
08036, Barcelona

Email: [rvalero@clinic.ub.es](mailto:rvalero@clinic.ub.es)

**Prof Brandt Stephan**

Department of Neurology  
Charity-Hospital  
Berlin  
Germany

Email: [stephan.brandt@charite.de](mailto:stephan.brandt@charite.de)

**Dr Peter John Victor**

Head, Medical Intensive Care Unit  
Christian Medical College Hospital  
Vellore 632 004  
India

Email: [peterjohnvictor@yahoo.com.au](mailto:peterjohnvictor@yahoo.com.au)

**Dr Hiroyuki Yokota**

Head, Emergency & Critical Care Medicine  
Nippon Medical School  
Tokyo  
Japan

Email: [yokota@nms.ac.jp](mailto:yokota@nms.ac.jp)

**WHO Secretariat****Dr Marie-Charlotte Bouesseau**

Adviser, HIS/SDS

Email: [bouesseaum@who.int](mailto:bouesseaum@who.int)

**Dr Edward Kelley**

Director, HIS/SDS

Email: [kelleye@who.int](mailto:kelleye@who.int)

**Dr Hernan Montenegro**

Coordinator, HIS/SDS

Email: [montenegroh@who.int](mailto:montenegroh@who.int)

**Dr Meena Nathan Cherian**

Adviser HIS/SDS/SCI

Email: [cherianm@who.int](mailto:cherianm@who.int)

**Mrs Harriete Jjuuko**

Administrative Assistant, HIS/SDS

Email: [jjuukoh@who.int](mailto:jjuukoh@who.int)

**Mrs Arlene Nina Lo Conte**

Secretary, HQ/HIS/SDS/SCI

Email : [locontea@who.int](mailto:locontea@who.int)

**Ms Emily Glander**

Intern, HIS/SDS

Email: [glander@who.int](mailto:glander@who.int)

**Ms Sandra Chaudron**

Observer

Email: [chaudrons@who.int](mailto:chaudrons@who.int)